These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 35812443)
41. Integrative analysis from multi-center studies identifies a weighted gene co-expression network analysis-based Tregs signature in ovarian cancer. Cao Y; Liu YL; Lu XY; Kai HL; Han Y; Zheng YL Environ Toxicol; 2024 Feb; 39(2):736-750. PubMed ID: 37713585 [TBL] [Abstract][Full Text] [Related]
42. Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody. Weaver JD; Stack EC; Buggé JA; Hu C; McGrath L; Mueller A; Wong M; Klebanov B; Rahman T; Kaufman R; Fregeau C; Spaulding V; Priess M; Legendre K; Jaffe S; Upadhyay D; Singh A; Xu CA; Krukenberg K; Zhang Y; Ezzyat Y; Saddier Axe D; Kuhne MR; Meehl MA; Shaffer DR; Weist BM; Wiederschain D; Depis F; Gostissa M Oncoimmunology; 2022; 11(1):2141007. PubMed ID: 36352891 [TBL] [Abstract][Full Text] [Related]
43. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point? Liu J; Zhang B; Zhang G; Shang D Front Immunol; 2024; 15():1345838. PubMed ID: 38449875 [TBL] [Abstract][Full Text] [Related]
44. Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. Tay C; Tanaka A; Sakaguchi S Cancer Cell; 2023 Mar; 41(3):450-465. PubMed ID: 36917950 [TBL] [Abstract][Full Text] [Related]
45. Prostate Cancer Immunotherapy-Finally in From the Cold? Runcie KD; Dallos MC Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308 [TBL] [Abstract][Full Text] [Related]
46. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Derhovanessian E; Adams V; Hähnel K; Groeger A; Pandha H; Ward S; Pawelec G Int J Cancer; 2009 Sep; 125(6):1372-9. PubMed ID: 19533748 [TBL] [Abstract][Full Text] [Related]
47. Treg programming and therapeutic reprogramming in cancer. Moreno Ayala MA; Li Z; DuPage M Immunology; 2019 Jul; 157(3):198-209. PubMed ID: 30866047 [TBL] [Abstract][Full Text] [Related]
48. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma. Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q Front Immunol; 2021; 12():693062. PubMed ID: 34497605 [TBL] [Abstract][Full Text] [Related]
49. Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion. D'Alise AM; Leoni G; De Lucia M; Langone F; Nocchi L; Tucci FG; Micarelli E; Cotugno G; Troise F; Garzia I; Vitale R; Bignone V; Di Matteo E; Bartolomeo R; Charych DH; Lahm A; Zalevsky J; Nicosia A; Scarselli E J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34824160 [TBL] [Abstract][Full Text] [Related]
50. Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients. Chen H; Yang W; Ji Z Front Immunol; 2023; 14():1171420. PubMed ID: 37063886 [TBL] [Abstract][Full Text] [Related]
51. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma. Zhou L; Fang H; Guo F; Yin M; Long H; Weng G J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868 [TBL] [Abstract][Full Text] [Related]
52. Cutibacterium acnes Induces the Expression of Immunosuppressive Genes in Macrophages and is Associated with an Increase of Regulatory T-Cells in Prostate Cancer. Davidsson S; Carlsson J; Greenberg L; Wijkander J; Söderquist B; Erlandsson A Microbiol Spectr; 2021 Dec; 9(3):e0149721. PubMed ID: 34937192 [TBL] [Abstract][Full Text] [Related]
53. Induced regulatory T cells in inhibitory microenvironments created by cancer. Whiteside TL Expert Opin Biol Ther; 2014 Oct; 14(10):1411-25. PubMed ID: 24934899 [TBL] [Abstract][Full Text] [Related]
54. A prognostic signature consisting of metabolism-related genes and SLC17A4 serves as a potential biomarker of immunotherapeutic prediction in prostate cancer. Li H; Gu J; Tian Y; Li S; Zhang H; Dai Z; Wang Z; Zhang N; Peng R Front Immunol; 2022; 13():982628. PubMed ID: 36325340 [TBL] [Abstract][Full Text] [Related]
55. Association between tumor mutation burden and immune infiltration in ovarian cancer. Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611 [TBL] [Abstract][Full Text] [Related]
56. Cellular immune responses towards regulatory cells. Larsen SK Dan Med J; 2016 Jan; 63(1):B5188. PubMed ID: 26726907 [TBL] [Abstract][Full Text] [Related]
57. The effects of TNF-α/TNFR2 in regulatory T cells on the microenvironment and progression of gastric cancer. Qu Y; Wang X; Bai S; Niu L; Zhao G; Yao Y; Li B; Li H Int J Cancer; 2022 Apr; 150(8):1373-1391. PubMed ID: 34766338 [TBL] [Abstract][Full Text] [Related]
58. Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer. Chaudhary B; Abd Al Samid M; al-Ramadi BK; Elkord E Expert Opin Biol Ther; 2014 Jul; 14(7):931-45. PubMed ID: 24661020 [TBL] [Abstract][Full Text] [Related]
59. PTPRO-related CD8 Dong H; Xie C; Yao Z; Zhao R; Lin Y; Luo Y; Chen S; Qin Y; Chen Y; Zhang H Front Immunol; 2022; 13():947841. PubMed ID: 36003382 [TBL] [Abstract][Full Text] [Related]
60. Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Ma Z; Zhang W; Dong B; Xin Z; Ji Y; Su R; Shen K; Pan J; Wang Q; Xue W Theranostics; 2022; 12(11):4965-4979. PubMed ID: 35836810 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]